Abstract No. 1234 A Phase I/II Study of the Angiogenesis Inhibitor Sorafenib in Cervical Cancer Patients Treated with Radiotherapy Naz Chaudary A. Fyles, C. Townsley, K. Han, R.P. Hill, S. Kim, W. Levin, H. MacKay, L. Manchul, I. Yeung, A. Oza, M. Milosevic Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada; and Departments of Radiation Oncology and Medical Biophysics, University of Toronto, Toronto, Canada Poster #12
4
Embed
Abstract No. 1234 A Phase I/II Study of the Angiogenesis Inhibitor Sorafenib in Cervical Cancer Patients Treated with Radiotherapy Naz Chaudary A. Fyles,
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Abstract No. 1234
A Phase I/II Study of the Angiogenesis Inhibitor
Sorafenib in Cervical Cancer Patients Treated with
Radiotherapy
Naz Chaudary
A. Fyles, C. Townsley, K. Han, R.P. Hill, S. Kim, W. Levin, H. MacKay, L. Manchul, I. Yeung, A. Oza, M. MilosevicRadiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada; and Departments of
Radiation Oncology and Medical Biophysics, University of Toronto, Toronto, Canada
Poster #12
AIM: To examine the efficacy and toxicity of sorafenib in patients with cervix cancer receiving RT and cisplatin chemotherapy (RTCT)
Sorafenib reduces tumor infiltration by myeloid cells that can contribute to vascular persistence and new vessel
formation during RT
The combination of RTCT and sorafenib was well tolerable similar to RTCT alone. Mechanism: Sorafenib offsets the RT resistance through an of hypoxia , by neutrophil recruitment to the tumor = allowing better treatment response.